Equities

ConvaTec Group PLC

CTEC:LSE

ConvaTec Group PLC

Health CareMedical Equipment and Services
  • Price (GBX)257.80
  • Today's Change0.00 / 0.00%
  • Shares traded21.88m
  • 1 Year change17.29%
  • Beta0.5527
Data delayed at least 20 minutes, as of Apr 26 2024 18:52 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ConvaTec Group PLC grew revenues 3.37% from 2.07bn to 2.14bn while net income improved 107.15% from 62.90m to 130.30m.
Gross margin56.04%
Net profit margin6.08%
Operating margin12.35%
Return on assets3.57%
Return on equity7.89%
Return on investment4.18%
More ▼

Cash flow in USDView more

In 2023, cash reserves at ConvaTec Group PLC fell by 46.20m. However, the company earned 367.40m from its operations for a Cash Flow Margin of 17.15%. In addition the company used 285.70m on investing activities and also paid 124.00m in financing cash flows.
Cash flow per share0.1346
Price/Cash flow per share19.16
Book value per share0.6612
Tangible book value per share-0.2115
More ▼

Balance sheet in USDView more

ConvaTec Group PLC has a Debt to Total Capital ratio of 43.67%, a lower figure than the previous year's 79.51%.
Current ratio1.62
Quick ratio0.8835
Total debt/total equity0.7753
Total debt/total capital0.4367
More ▼

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 9.77% and 105.90%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)2.19%
Div growth rate (5 year)31.41%
Payout ratio (TTM)70.15%
EPS growth(5 years)-7.80
EPS (TTM) vs
TTM 1 year ago		105.40
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.